Clinical Trial: A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title:

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia

Detailed Summary:
Sponsor: Kissei Pharmaceutical Co., Ltd.

Current Primary Outcome: Serum phosphate concentrations [ Time Frame: 12 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

• Change from baseline in serum calcium concentrations [ Time Frame: 12 weeks ]
• Change from baseline in serum calcium × phosphate product [ Time Frame: 12 weeks ]
• Change from baseline in serum intact-PTH concentrations [ Time Frame: 12 weeks ]

Original Secondary Outcome: Same as current

Information By: Kissei Pharmaceutical Co., Ltd.

Dates:
Date Received: May 7, 2013
Date Started:
Date Completion:
Last Updated: November 11, 2014
Last Verified: November 2014